Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus ... subcutaneous semaglutide 7.2 mg compared with Wegovy and placebo in adults with obesity.

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Ozempic came out with a higher-strength, 2 mg dose that was not approved until after this trial was over. Considering GLP-1 agonists tend to perform better at higher doses, it remains to be seen ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially lower the risk of opioid overdoses. But now, a new study finds that taking ...